Drug Trial Radar · NCT01381796
Compare PK and Bioavailability of 2 NP101 Patches With Oral Imitrex in Healthy Adults
Last checked: Nov 19, 2026Latest source record: Oct 12, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
63
Actual
Start
Dec 2009
Primary completion
Sep 2010
Study completion Sep 2010
Sponsor
- Lead sponsor
- NuPathe Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 27, 2011
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Crossover
- Masking
- None
- Primary purpose
- Basic science
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this research is to: 1. Compare two study patches having minor differences in patch components 2. Compare the pharmacokinetics (PK - how the body absorbs, metabolizes and eliminates medication) of NP101 (study patches) versus a currently approved oral formulation of Imitrex 3. Collect resistance data during application of NP101 (study patch)
Conditions
- Compare Bioequivalence Patches Previously Used in the NP101-007 Study
Interventions
NP101Drug
comparison of NP101 with minor patch modifications
sumatriptan succinateDrug
tablet, 100 mg
Primary outcomes
What the sponsor says the trial is designed to measure.
- Analysis of variance (ANOVA) will be used to compare AUC0-inf and Cmax values between treatments. AUC0-last, Tmax and t1/2 will be summarized descriptively.Time frame: Blood samples (4 mL per sample) for PK analysis will be collected for all treatments by catheter or venipuncture into EDTA collection tubes for the determination of sumatriptan concentrations in plasma for each treatment.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Prism Research, LLC
Saint Paul, Minnesota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.